(August 18, 2016, 12:45 PM EDT) -- WASHINGTON, D.C. — Findings by the Patent Trial and Appeal Board that 23 claims of a patented composition for tigecycline and an acid or buffer are not obvious were not erroneous, the Federal Circuit U.S. Court of Appeals concluded Aug. 16 (Apotex Inc. v. Wyeth LLC, No. 15-1871, Fed. Cir.; 2016 U.S. App. LEXIS 14991)....